Concordia’s Donnatal promoted in U.S.

by • June 15, 2017 • Business Focus, Deals/M&A/CollaborationComments Off on Concordia’s Donnatal promoted in U.S.717

Oakville, Ont.-based Concordia International said the company’s adjunctive therapy for irritable bowel syndrome, is now being promoted in the certain United States locations.

Concordia entered into an agreement in January with RedHill Biopharma Ltd., to co-promote the drug Donnatal in the U.S.

Under the terms of the co-promotion agreement, RedHill will incur the sales and marketing costs associated with promotional activities for Donnatal, while Concordia will provide materials and samples.

Concordia will keep all revenue up to a predetermined level of sales. Only after reaching that predetermined level will revenue be shared between Concordia and RedHill.

“We are excited that RedHill is moving forward with its promotion of Donnatal to potential prescribers in the U.S.,” said Allan Oberman, chief executive officer of Concordia.”We believe this cost-effective partnership can leverage RedHill’s experienced team in gastroenterology sales, raise the product’s profile, and potentially allow Donnatal to reach more patients.”

Donnatal is used as adjunctive therapy for irritable bowel syndrome, a condition characterized by abdominal pain, bloating, and diarrhea or constipation, and acute enterocolitis. It may also be useful as adjunctive therapy for duodenal ulcer, according to Concordia.

Concordia is an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products. It sells its products in more than 90 countries and has a diversified portfolio of more than 200 established off-patent products.

Concordia also markets Photofrin for the treatment of certain rare forms of cancer. The firm operates out of facilities in Oakville, Ont. and, through its subsidiaries, operates out facilities in Bridgetown, Barbados; London, England and Mumbai, India.

RedHill is a specialty biopharmaceutical company headquartered in Israel. It is focused on the development and commercialization in the U.S. of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer.

Comments are closed.